Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Bacillus Calmette-Guerin (BCG) infections following intravesical BCG immunotherapy: a systematic review protocol.
Syst Rev
January 2025
Department of Medicine, Division of Infectious Diseases, Duke University, 148 Hanes House, 315 Trent Dr, Durham, NC, 27710, USA.
Background: Although intravesical Bacillus Calmette-Guerin (BCG) immunotherapy usually exhibits a favorable safety profile, it can lead to the development of BCG infections, both localized and disseminated. Understanding of BCG infections following intravesical BCG immunotherapy is limited because of the lack of consensus definitions of BCG infections and limited post-instillation follow-up. We aim to perform a systematic review of the literature of BCG infections following intravesical BCG immunotherapy to elucidate the epidemiology, risk factors, and outcomes of BCG infections.
View Article and Find Full Text PDFTopical and Intralesional Treatments for Skin Metastases and Locoregionally Advanced Melanoma.
Cancers (Basel)
December 2024
Dermatology Department, Complejo Asistencial Universitario de León, 24008 León, Spain.
Cutaneous melanoma is a malignant neoplasm with local and distant metastatic potential. When feasible, surgery is the first line of treatment in locoregionally advanced disease. Topical and intralesional treatments can be an alternative second-line treatment.
View Article and Find Full Text PDFExploring radiotherapy combined with a radiosensitizer for Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ.
Transl Androl Urol
November 2024
Department of Urology, Center for Urologic Cancer, Hospital/Division of Tumor Immunology, Research Institute, National Cancer Center, Goyang, Gyeonggi-do, Republic of Korea.
Comment on 'Effects of Bacillus pumilus on growth performance, serum indexes and muscle development-related gene expression of weanling Jintang black goat'.
Benef Microbes
August 2024
Food Technology Department, Faculty of Agriculture, Sultan Ageng Tirtayasa University, Serang 42124, Indonesia.
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer.
Bladder Cancer
September 2023
Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
Background: Despite recent drug development for non-muscle invasive bladder cancer (NMIBC), few therapies have been approved by the US Food and Drug Administration (FDA), and there remains an unmet clinical need. Bacillus Calmette-Guerin (BCG) supply issues underscore the importance of developing safe and effective drugs for NMIBC.
Objective: On November 18-19, 2021, the FDA held a public virtual workshop to discuss NMIBC research needs and potential trial designs for future development of effective therapies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!